Holles Natalie C.
SEC-identified person · CIK 1580111 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Leonabio, Inc. LONA | Director | filed 2026 - 2026 |
| Aura Biosciences, Inc. AURA | Director · See Remarks | filed 2026 - 2026 |
| Day One Biopharmaceuticals, Inc. DAWN | Director | filed 2021 - 2026 |
| Third Harmonic Bio, Inc. THRD | Director · CEO | filed 2022 - 2025 |
| Rubius Therapeutics, Inc. RUBY | Director | filed 2019 - 2022 |
| Allakos Inc. ALLK | Director | filed 2020 - 2021 |
| Audentes Therapeutics, Inc. BOLD | Senior Vice President, COO | filed 2016 - 2020 |
| Hyperion Therapeutics INC HPTX | SVP, Corp & Business Dev | filed 2013 - 2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.